Ergomed Plc (ERGO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Ergomed Plc (ERGO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH191030D
  • |
  • Pages: 49
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Ergomed Plc (Ergomed), formerly Ergomed Clinical Research Ltd is a drug development and clinical research services provider. The company provides service portfolio such as regulatory and quality management, biostatistics, study management, clinical data management, medical writing, and others. It also provides late phase services such as on-site or remote monitoring, product related pharmacovigilance services, safety management and other supportive services. Ergomed offers co-development services in the treatment areas of oncology and neurology, orphan diseases, and others. The company operates in Croatia, Germany, Russia, the US, Serbia, Poland, the UAE and India, among others. Ergomed is headquartered in Guildford, the UK.

Ergomed Plc (ERGO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ergomed Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ergomed Plc, Medical Devices Deals, 2012 to YTD 2018 10

Ergomed Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Ergomed Plc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Haemostatix Raises USD0.1 Million in Venture Financing 13

Partnerships 15

Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 15

Ergomed Enters into Co-Development Agreement with Asarina Pharma 16

Ergomed Enters into Co-Development Agreement with Dilaforette 17

Ergomed Clinical Research Enters Into Co-Development Agreement With Ferrer 18

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 19

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 20

Cel-Sci Expands Co-Development Agreement with Ergomed 21

Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 22

Licensing Agreements 23

Ergomed Enters into Licensing Agreement with Boryung Pharma 23

Equity Offering 24

Ergomed Raises USD5.5 Million in Private Placement of Shares 24

Ergomed Raises USD2.2 Million in Private Placement of Shares 25

Ergomed Announces Underwriter's Exercise of Over-Allotment Option of Private Placement for USD10.4 Million 26

Ergomed Raises USD19 Million in IPO 27

Acquisition 28

Ergomed Acquires PSR Group for USD6.7 Million 28

Ergomed Acquires Dr.Oestreich +Partner and Gesellschaft fur angewandte Statistik + Datenanalyse 29

Ergomed Acquires Haemostatix 30

Ergomed Acquires Sound Opinion 32

Ergomed Plc-Key Competitors 33

Ergomed Plc-Key Employees 34

Ergomed Plc-Locations And Subsidiaries 35

Head Office 35

Other Locations & Subsidiaries 35

Recent Developments 37

Financial Announcements 37

Apr 11, 2018: Ergomed: Unaudited Preliminary Results for the year ended 31 December 2017 37

Sep 18, 2017: Ergomed: Unaudited Interim results for the six months ended 30 June 2017 38

Mar 28, 2017: Ergomed: Unaudited Preliminary Results for the year ended 31 December 2016 39

Jan 17, 2017: Ergomed to report very strong 2016 revenue growth and order backlog; Poised for significant clinical milestones in 2017 40

Corporate Communications 41

Jul 02, 2018: Ergomed Names Stuart Jackson As Chief Financial Officer 41

Dec 15, 2017: Stephen Stamp appointed as CEO and Jan Petracek as COO 43

Dec 15, 2017: Ergomed Board appointed Stephen Stamp as CEO and Jan Petracek as COO 44

Apr 13, 2017: Ergomed Announces Board and Management Changes 45

Other Significant Developments 46

Jun 15, 2018: Ergomed Announces Registered Office Address Change 46

Mar 05, 2018: Ergomed: Trading Update and Notice of Preliminary Results 47

Jan 25, 2018: Ergomed 2017 Trading Update 48

Appendix 49

Methodology 49

About GlobalData 49

Contact Us 49

Disclaimer 49

List of Figures

Ergomed Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ergomed Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Ergomed Plc, Medical Devices Deals, 2012 to YTD 2018 10

List of Tables

Ergomed Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Ergomed Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Ergomed Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Ergomed Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Ergomed Plc, Medical Devices Deals, 2012 to YTD 2018 10

Ergomed Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Haemostatix Raises USD0.1 Million in Venture Financing 13

Ergomed Enters into Co-Development Agreement with Allergy Therapeutics 15

Ergomed Enters into Co-Development Agreement with Asarina Pharma 16

Ergomed Enters into Co-Development Agreement with Dilaforette 17

Ergomed Clinical Research Enters Into Co-Development Agreement With Ferrer 18

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine In HIV/HPV Co-Infected Patients With Peri-Anal Warts 19

Cel-Sci Enters Into Co-Development Agreement With Ergomed For Multikine 20

Cel-Sci Expands Co-Development Agreement with Ergomed 21

Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 22

Ergomed Enters into Licensing Agreement with Boryung Pharma 23

Ergomed Raises USD5.5 Million in Private Placement of Shares 24

Ergomed Raises USD2.2 Million in Private Placement of Shares 25

Ergomed Announces Underwriter's Exercise of Over-Allotment Option of Private Placement for USD10.4 Million 26

Ergomed Raises USD19 Million in IPO 27

Ergomed Acquires PSR Group for USD6.7 Million 28

Ergomed Acquires Dr.Oestreich +Partner and Gesellschaft fur angewandte Statistik + Datenanalyse 29

Ergomed Acquires Haemostatix 30

Ergomed Acquires Sound Opinion 32

Ergomed Plc, Key Competitors 33

Ergomed Plc, Key Employees 34

Ergomed Plc, Subsidiaries 35

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Ergomed Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 18130
Site License
USD 500 INR 36260
Corporate User License
USD 750 INR 54390

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com